Healthcare and Pharmaceuticals: Pipelines, Patents and Regulation

What you will learn

• The main sub-sectors of healthcare and how their business models differ.
• The stages of drug development and the role of regulators such as the EMA and FDA.
• How patents and loss of exclusivity create a "patent cliff".
• How to value a pipeline drug with a risk-adjusted net present value (rNPV).

Explanation

Healthcare is often called defensive because people need medicines in every phase of the cycle. But inside the sector, risks are very different:

• Pharmaceuticals: large companies with many approved drugs, high gross margins and high research and development (R&D) spending.
• Biotechnology: often one or a few drug candidates, frequently without revenue. Value depends on trial results, so single events can move the share price very strongly.
• Medical technology: devices and diagnostics, with product cycles and hospital budgets as drivers.
• Healthcare services: hospitals, laboratories, insurers in some markets; driven by volumes and reimbursement rates.

Drug development

A new drug passes through preclinical tests and three clinical phases. Phase I tests safety in a small group. Phase II tests whether the drug works and which dose is right. Phase III confirms efficacy and safety in large trials. The company then files for approval. In the EU, the European Medicines Agency (EMA) evaluates most new medicines in the centralised procedure and the European Commission grants the authorisation; in the US the Food and Drug Administration (FDA) decides. Many candidates fail at each stage, and development can take many years. Approval is not the end: in Germany, for example, new drugs undergo an early benefit assessment that influences the price paid by statutory health insurers; check the current rules.

Patents and exclusivity

A patent usually lasts 20 years from the filing date. Because companies file early, much of that time passes during development, so the protected selling period after launch is much shorter. Extra protections exist: in the EU, a supplementary protection certificate can extend protection for up to five years, and regulatory data protection blocks copies for a period after approval. In 2025–2026 the EU negotiated a reform of its pharmaceutical legislation that changes these periods (final adoption was still pending in 2026), so check the current rules before using exact numbers.

When protection ends, loss of exclusivity follows: generics (copies of chemical drugs) or biosimilars (similar versions of biological drugs) enter and prices and volumes can fall quickly. A patent cliff is a period when a company loses exclusivity on products that make up a large share of revenue.

Key analysis questions

• Concentration: what share of revenue comes from the top one to three drugs?
• Exclusivity schedule: when does each major product lose protection? Companies publish this in their reports.
• Pipeline: how many late-stage (Phase III) candidates could replace lost revenue?
• R&D ratio: R&D spending ÷ revenue, and what it has produced.

Risk-adjusted NPV

Net present value (NPV) was covered in the stocks course (discounted cash flow). For a drug candidate, the cash flows only happen if it succeeds, so analysts multiply by the probability of reaching the market and subtract development costs weighted by the probability that they will be spent:

rNPV = P(approval) × NPV if approved − expected remaining development costs

Worked example

Hypothetical example: a candidate at the start of Phase II. All probabilities and costs are invented for practice, not industry statistics. For simplicity, costs are not discounted and taxes are ignored.

• NPV of cash flows if approved: €2,000m (already discounted to today).
• Success probabilities: Phase II 35%, Phase III 60%, approval 90%.
• Costs: Phase II €60m (spent now), Phase III €300m, filing €20m.

1. Probability of reaching the market = 0.35 × 0.60 × 0.90 = 0.189 (18.9%).
2. Expected value of success = 0.189 × €2,000m = €378m.
3. Expected costs: Phase II €60m (certain); Phase III spent only if Phase II succeeds: 0.35 × €300m = €105m; filing only after Phase III success: 0.35 × 0.60 = 0.21, so 0.21 × €20m = €4.2m.
4. rNPV = €378m − €60m − €105m − €4.2m = €208.8m ≈ €209m.

Patent cliff check: a hypothetical company has group revenue of €10bn; its top drug sells €3bn and loses exclusivity next year. If it loses 70% of those sales within two years, revenue falls by €2.1bn, which is 21% of group revenue. The pipeline must replace that just for the company to stand still.

Common mistake

Practice activity

A hypothetical drug candidate is about to start Phase III. If approved, the NPV of its cash flows is €800m. Probability of Phase III success 55%, probability of approval after that 90%. Phase III costs €150m (spent now) and filing costs €10m (only after Phase III success). Calculate the probability of reaching the market and the rNPV.

Key takeaways

• Healthcare is defensive as a whole, but biotech and single-product companies carry high event risk.
• Drugs move through Phase I, II and III before approval by regulators such as the EMA and FDA.
• Patents and exclusivity periods end; check each major product's loss-of-exclusivity date.
• rNPV weights future cash flows and development costs by the probability of success.

Next step

The next lesson compares consumer staples and consumer discretionary companies through brands, margins and demand.